Montis Biosciences

Montis Biosciences is a biotechnology company developing next-generation therapeutics that harness the dual biology of complement C1q by simultaneously targeting the complement and myeloid axes, two fundamental drivers of autoimmune and neurodegenerative diseases.

The company’s pipeline targets neuroinflammatory diseases, with a lead program in Guillain-Barré syndrome, a debilitating autoimmune neuropathy, that is driven by complement and macrophage activation. In parallel, the company is progressing its antibodies in other autoimmune, neurodegenerative and ophthalmic diseases, where both C1q-driven mechanisms are increasingly recognized as key contributors to disease onset and progression.

Montis Biosciences is headquartered in Leuven, Belgium, and is supported by a world-class investor syndicate including DROIA Ventures, Pfizer Ventures, Polaris Innovation Fund, ALSA Ventures and VIB.